Quick Answer
Phio Pharmaceuticals Corp. reported R&D Expense of $4.62 million for fiscal year 2025.
Phio Pharmaceuticals Corp. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $4.62M | +26.8% |
| 2024 | $3.64M | -42.5% |
| 2023 | $6.33M | -9.7% |
| 2022 | $7.01M | -21.1% |
| 2021 | $8.89M | +139.1% |
| 2020 | $3.72M | -13.6% |
| 2019 | $4.30M | -0.6% |
| 2018 | $4.33M | -19.4% |
| 2017 | $5.37M | -0.8% |
| 2016 | $5.42M | -21.8% |
| 2015 | $6.92M | +21.9% |
| 2014 | $5.68M | -67.8% |
| 2013 | $17.65M | +68.9% |
| 2012 | $10.45M | +57.8% |
| 2011 | $6.62M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.18M | +83.4% | +10.0% |
| June 30, 2025 | $1.07M | +24.0% | +21.2% |
| March 31, 2025 | $886.0K | -22.8% | +37.6% |
| September 30, 2024 | $644.0K | -64.4% | -25.6% |
| June 30, 2024 | $866.0K | -37.4% | -24.6% |
| March 31, 2024 | $1.15M | -46.2% | -36.5% |
| September 30, 2023 | $1.81M | -27.9% | +30.7% |
| June 30, 2023 | $1.38M | +6.1% | -35.2% |
- Phio Pharmaceuticals Corp. showed an increase of +26.8% in R&D Expense compared to the prior fiscal year.
- Over the 2011–2025 period, Phio Pharmaceuticals Corp.’s r&d expense has declined by 30.3% (from $6.62 million to $4.62 million).
- The most recent figure is from Phio Pharmaceuticals Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: